Themis has established a versatile technology platform for the discovery, development and production of vaccines as well as other immune system activation approaches. Our clinical pipeline initially focuses on infectious diseases, addressing the need for novel vaccines to prevent both emerging and large market diseases with a view towards cancer and other immunological diseases.
Emerging diseases pose a rapidly increasing threat to developing and developed countries alike. Climate change and mass tourism are fueling this raise in outbreaks worldwide and for many diseases there are no efficient treatments or vaccinations available yet. Vaccines are one of the most important, safe and efficient interventions to protect people from illness, disability and death.